ModernaNASDAQ: MRNA

Moderna (MRNA) shares edged higher Tuesday after the biotech firm received a federal grant to develop a vaccine to prevent bird flu in humans.

Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine stockpiles as health officials and experts worry the highly contagious H5N1 influenza virus tearing through poultry farms and cattle herds could spread to humans.

If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.

Moderna recently won approval for a second product -- one with a $10 billion market. Pfizer offers a juicy dividend yield and better growth prospects than you might think.

Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.